Cargando…

Association of HLA-G 3′UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer

Microenvironmental factors such as non-classical human leukocyte antigen-G (HLA-G) have been associated with cancer invasiveness and metastatic progression. HLA-G expression has been associated with specific single-nucleotide polymorphisms (SNP) in HLA-G 3′untranslated region (UTR) in several diseas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scarabel, Lucia, Polesel, Jerry, De Mattia, Elena, Buonadonna, Angela, D’Andrea, Mario Rosario, Cecchin, Erika, Toffoli, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788252/ https://www.ncbi.nlm.nih.gov/pubmed/36559230 http://dx.doi.org/10.3390/pharmaceutics14122737

Ejemplares similares

HLA-G 3′UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer
por: Garziera, Marica, et al.
Publicado: (2017)

Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI
por: De Mattia, Elena, et al.
Publicado: (2019)

IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm
por: De Mattia, Elena, et al.
Publicado: (2021)

Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
por: De Mattia, Elena, et al.
Publicado: (2018)

HLA-G 3’UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment
por: Garziera, Marica, et al.
Publicado: (2015)

Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis
por: Bignucolo, Alessia, et al.
Publicado: (2021)

Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy
por: Scarabel, Lucia, et al.
Publicado: (2020)

Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy
por: De Re, Valli, et al.
Publicado: (2014)

The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity
por: De Mattia, Elena, et al.
Publicado: (2023)

Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis
por: Dalle Fratte, Chiara, et al.
Publicado: (2023)

Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC
por: Scarabel, Lucia, et al.
Publicado: (2022)

Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L
por: Labriet, Adrien, et al.
Publicado: (2017)

Genetic biomarkers for hepatocellular cancer risk in a caucasian population
por: De Mattia, Elena, et al.
Publicado: (2017)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients
por: Dreussi, Eva, et al.
Publicado: (2016)

Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients
por: Labriet, Adrien, et al.
Publicado: (2019)

Predictive and Prognostic Value of Oncogene Mutations and Microsatellite Instability in Locally-Advanced Rectal Cancer Treated with Neoadjuvant Radiation-Based Therapy: A Systematic Review and Meta-Analysis
por: De Mattia, Elena, et al.
Publicado: (2023)

Hypoxic Modulation of HLA-G Expression through the Metabolic Sensor HIF-1 in Human Cancer Cells
por: Garziera, Marica, et al.
Publicado: (2017)

Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk
por: De Mattia, Elena, et al.
Publicado: (2022)

A Panel of Tumor Biomarkers to Predict Complete Pathological Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer
por: Dalle Fratte, Chiara, et al.
Publicado: (2022)

XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer
por: CUI, CHENGXU, et al.
Publicado: (2014)

Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
por: Rong, Xuetong, et al.
Publicado: (2022)

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2011)

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)
por: El-Deiry, Wafik S., et al.
Publicado: (2019)

Efficacy and safety of FOLFIRI and biotherapy versus FOLFIRI alone for metastatic colorectal cancer patients: A meta-analysis
por: Jiang, Yangbo, et al.
Publicado: (2017)

Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting()()()
por: Ma, Cheng-Jen, et al.
Publicado: (2018)

FOLFIRI(®) and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms
por: Bécouarn, Yves, et al.
Publicado: (2014)

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2017)

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
por: Bignucolo, A., et al.
Publicado: (2023)

Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer
por: Zanusso, Chiara, et al.
Publicado: (2017)

FOLFIRI as second-line treatment of metastatic biliary tract cancer patients
por: Caparica, Rafael, et al.
Publicado: (2019)

Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients
por: Dreussi, Eva, et al.
Publicado: (2016)

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
por: Carola, Candice, et al.
Publicado: (2018)

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment
por: Bignucolo, Alessia, et al.
Publicado: (2017)

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
por: Macarulla, T, et al.
Publicado: (2015)

Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer
por: Denda, Tadamichi, et al.
Publicado: (2019)

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer
por: Joulain, F, et al.
Publicado: (2013)

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2018)

UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI
por: Hsieh, Yi-Chien, et al.
Publicado: (2021)

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hg7mb6k1phv5k7fhbbdr4ncgq8